GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases

Mitochondrion. 2015 Jan:20:34-42. doi: 10.1016/j.mito.2014.10.006. Epub 2014 Nov 1.

Abstract

Pyruvate therapy is a promising approach for the treatment of mitochondrial diseases. To identify novel biomarkers for diagnosis and to evaluate therapeutic efficacy, we performed microarray analysis of 2SD cybrid cells harboring a MELAS-causing mutation and control cells treated with either lactate or pyruvate. We found that expression and secretion of growth differentiation factor 15 (GDF15) were increased in 2SD cells treated with lactate and that serum GDF15 levels were significantly higher in patients with mitochondrial diseases than in those with other diseases, suggesting that GDF15 could be a useful marker for diagnosis and evaluating the therapeutic efficacy of pyruvate.

Keywords: Biomarker; Cybrid; GDF15; Microarray; Mitochondrial diseases; Pyruvate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / analysis
  • Drug Monitoring / methods*
  • Gene Expression Profiling
  • Growth Differentiation Factor 15 / analysis*
  • Humans
  • Microarray Analysis
  • Mitochondrial Diseases / diagnosis*
  • Mitochondrial Diseases / drug therapy*
  • Pyruvic Acid / metabolism*
  • Pyruvic Acid / therapeutic use

Substances

  • Biomarkers
  • GDF15 protein, human
  • Growth Differentiation Factor 15
  • Pyruvic Acid